ArticleHeliyon2024
Stellate ganglion block therapy in management of ventricular electrical storm: A case report.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasound-guided stellate ganglion block for refractory sympathetically mediated arrhythmia following acute myocardial infarction: a tutorial and examples.Frontiers in cardiovascular medicine · 2026Article
- Sympathetic nerve block as an add-on therapy for intervention and prevention of cerebral vasospasm after subarachnoid hemorrhage.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sympathetic overactivity is a recognized underlying mechanism contributing to the pathogenesis of ventricular electrical storm (VES). The growing body of evidence supports the efficacy of stellate ganglion block (SGB) in attenuating myocardial sympathetic tone, rendering it a valuable adjunctive therapy for managing VES. This case report presents the clinical details of a 60-year-old patient admitted for ventricular tachycardia (VT), necessitating the implantation of an implantable cardioverter defibrillator (ICD) to mitigate the risk of fatal ventricular arrhythmias (VAs). Subsequently, the patient received repeated antitachycardia pacing (ATP) therapy due to persistent symptomatic VT episodes. SGB was contemplated due to the patient's hemodynamic instability during episodes of VT and the ineffectiveness of pharmacotherapy. Initially, complete suppression of VT was achieved for 3 days using local anesthesia, followed by partial suppression via pulsed radiofrequency (PRF), culminating in sustained relief for 3 months following continuous radiofrequency (CRF) therapy. Different methods of SGB elicited varied responses in this patient. CRF appeared to be more effective than PRF and conventional local anesthetics. CRF ablation of the stellate ganglion for refractory VAs offers a potential therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.